The American College of Rheumatology (ACR) is apprehensive that “without substantial changes, the demonstration program could disrupt patient access to care, worsen the rheumatology workforce shortage, and exacerbate geographic disparities in access to medical care.”
In recently submitted comments to CMS, the American College of Rheumatology (ACR) expressed concern that the proposed International Pricing Index (IPI), announced November 2018, may disrupt patient access to care.
Specifically, ACR is apprehensive that “without substantial changes, the demonstration program could disrupt patient access to care, worsen the rheumatology workforce shortage, and exacerbate geographic disparities in access to medical care.”
The IPI proposal would allow CMS to implement a reference pricing structure over a 5-year period from 2020-2025, which would enable Medicare to more closely align its payment amount for selected Part B drugs with prices paid in other nations, as well as allow for private-sector negotiations of drugs. CMS believes that the proposal could generate 30% in cost savings, although this figure does not include the prices of biosimilars; instead, it only compares the prices of reference products.
ACR explained in its letter that although it does not have a policy on international reference pricing, the group does support Medicare using its authority to lower drug prices, but does not support mandatory demonstration projects.
“Our current policy is that we support Medicare having the ability to negotiate for reduced drug prices; however, there are many specific pricing mechanisms described in the [IPI] that the ACR cannot support without having specific details on the policy,” read the ACR comment letter.
The organization suggested several modifications to the program:
“We appreciate the opportunity to provide input on the proposed IPI model and are encouraged by the agency’s efforts to make needed therapies more affordable for patients,” said Paula Marchetta, MD, MBA, president of ACR, in a statement. “However, we believe that changes must be made to ensure the proposal does not result in significant disruptions in patient care for the 54 million Americans who live with rheumatic disease.”
The ACR is not the only organization that has expressed concern about the index, as just last month 339 patient, provider, and caregiver groups, on behalf of the Part B Access for Seniors and Physicians Coalition, sent a letter to Congress encouraging lawmakers to block the implementation of the index.
Comments on the IPI model have closed, and CMS will aim to issue a proposed rule this spring.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.